Drugs / IDL-2965
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03949530 | Apr 2019 → Mar 2020 | idiopathic pulmonary fibrosis | Indalo Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDL-2965 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03949530 ↗ |
| Route | Oral | “IDL-2965 is an oral integrin antagonist antifibrotic being studied as a potential treatment for IPF and Nonalcoholic Steatohepatitis (NASH).” NCT03949530 ↗ |